CD8A and neoplasm: Clinically, both circulating and liver/tumor-infiltrating E. hirae-reactive CD8+ T cell responses were observed only in HBV-related hepatocellular carcinoma (HCC) patients but not in healthy individuals, and the frequency of these cells was positively corelated with the PFS time of the HCC patients.